Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Slides:

Advertisements

Similar presentations

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study Garcia-Manero G et al. Proc ASH 2010;Abstract 603.

Advertisements

Wilson WH et al. Proc ASH 2012;Abstract 686.

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

1Coiffier B et al. Proc ASH 2010;Abstract 114.

Novel AKT Inhibitor Afuresertib in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity.

Ibrutinib: First-in Class Inhibitor of BTK  Forms a specific and irreversible bond with cysteine-481 in BTK  Highly potent BTK inhibition at IC 50 =

Palumbo A et al. Proc ASH 2012;Abstract 446.

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.

Roberts AW et al. Proc ASH 2014;Abstract 325.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post- Essential.

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.

Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.

The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and is Tolerable in Treatment- Naïve.

Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients with Previously.

Ibrutinib (PCI-32765) First-In-Class BTK Inhibitor IM Los Angeles 18 Jan

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

Final Results of a Phase 1 Study of Idelalisib (GS-1101), a Selective Inhibitor of Phosphatidylinositol 3-Kinase p110 Delta (PI3K), in Patients with Relapsed.

Activity and Tolerability of Afatinib (BIBW 2992) and Cetuximab in NSCLC Patients with Acquired Resistance to Erlotinib or Gefitinib Janjigian YY et al.

Viardot A et al. Proc ASH 2014;Abstract 4460.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Kanti R. Rai, MD NSLIJ-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Hematology Highlights 2013 Expert Reviews of the.

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.

Ruan J et al. Proc ASH 2013;Abstract 247.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

Updated Results of a Phase I First-in-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic.

The Bruton’s Tyrosine Kinase Inhibitor PCI is Highly Active as Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

Treon SP et al. Proc ASH 2013;Abstract 251.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Idelalisib (GS- 1101) in Combination with Rituximab and/or Bendamustine.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.

Ibrutinib in Combination with Rituximab (iR) Is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High- Risk Chronic Lymphocytic.

Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update Cortes.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.

Kantarjian HM et al. Proc ASH 2012;Abstract Long-Term Follow-Up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid.

Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH.

Shustov AR et al. Proc ASH 2010;Abstract 961.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study1 Phase I Study of Rituximab,

IMBRUVICA® (ibrutinib)

New Findings in Hematology: Independent Conference Coverage

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

Cortes JE et al. Proc ASCO 2010;Abstract 6502.

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Ferrajoli A et al. Proc ASH 2010;Abstract 1395.

Coiffier B et al. Proc ASH 2010;Abstract 857.

Badoux X et al. Proc ASCO 2010;Abstract 6508.

Seymour JF et al. Proc ASH 2013;Abstract 872.

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Advani RH et al. Proc ASH 2011;Abstract 443.

Wiestner A et al. Proc ICML 2013;Abstract 008.

Presentation transcript:

Byrd JC et al. Proc ASCO 2011;Abstract 6508. Activity and Tolerability of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Interim Results of a Phase Ib/II Study Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Background Bruton's Tyrosine Kinase (Btk): B-cell antigen receptor (BCR) signaling is required for tumor expansion and proliferation. Btk is an essential element of the BCR signaling pathway. Mutations in Btk prevent B-cell maturation. Inhibitors of Btk block BCR signaling and induce apoptosis. PCI-32765: Forms a specific and irreversible bond with cysteine-481 in Btk. Orally bioavailable with daily dosing resulting in 24-hour target inhibition. Inhibits BCR signaling and active in spontaneous canine B-cell lymphoma. In CLL cells promotes apoptosis, inhibits ERK1/AKT phosphorylation, NF-kB DNA, binding, CpR mediated proliferation. Inhibits CLL cell migration and adhesion. Byrd JC et al. Proc ASCO 2011;Abstract 6508.

PCYC 1102 Study Design Single-agent, multicohort study of PCI-32765 in two subject populations with symptomatic CLL/SLL: Treatment-naïve, aged ≥65 years Dose (May 2010 – March 2011): 420 mg/day until progression Relapsed/refractory Dose #1 (May – September 2010): 420 mg/day until progression Dose #2 (October 2010 – March 2011): 840 mg/day until progression Objectives: To determine the response rate, duration of response, progression-free survival, PK/PD and toxicity of PCI-32765 in separate cohorts of CLL/SLL subjects. To examine the influence of genomic features on clinical response to PCI-32765. Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Best Response and Initial (Cycle Two) Assessment Treatment-Naïve (420 mg/d) Relapsed/Refractory (420mg/d) 80% 60% 40% 20% 0% 80% 60% 40% 20% 0% 67% 5% 59% 48% Response Rate % Response Rate % 4% 41% 33% 62% 24% 19% 19% 44% Cycle 2 (n = 21) Best Response (n = 21) Cycle 2 (n = 27) Best Response (n = 27) CR PR Nodal Response Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Best Response Overall response rate 67% 48% Complete response 5% 4% Treatment-naïve 420 mg/day (n = 21) Relapsed/refractory (n = 27) Overall response rate 67% 48% Complete response 5% 4% Partial response 62% 44% Nodal response 19% 41% Stable disease 10% Progressive disease 0% Not estimable Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Initial (Cycle Two) Assessment by Treatment Setting and Dose Treatment-naïve 420 mg/day (n = 21) Relapsed/refractory (n = 27) 840 mg/day (n = 33) Complete response Partial response 24% 19% 15% Nodal response 33% 59% 64% Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Select Adverse Events ≤ Grade 3 Treatment-naïve 420 mg/day (n = 23) Relapsed/refractory (n = 27) Diarrhea 48% 70% Nausea 39% 33% Vomiting 17% 22% Dyspepsia 19% Bruising 4% Muscle spasms 26% Rash 11% Upper respiratory infection 13% 37% Fatigue Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Author Conclusions Toxicity of PCI-32765 is modest, generally allowing extended continuous dosing in patients with CLL. The majority of adverse events were Grade 1 or 2 in severity. Cytopenias were relatively uncommon in patients treated with PCI-32765 at 420 mg/day. Grade 3/4 neutropenia was more common in the 840-mg group. These interim Phase II data confirm that PCI-32765 is highly active in patients with treatment-naïve and relapsed/refractory CLL/SLL. 2008 CLL IWG objective responses (PR + CR) and nodal responses appear to be durable and independent of high-risk genomic features. A high proportion (81%) of patients with relapsed/refractory disease are free of disease progression beyond six months (420 mg/day cohort) and continue on therapy. Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Investigator Commentary: The Results from a Phase Ib/II Study of the Btk Inhibitor PCI-32765 in CLL Signaling through the B-cell receptor is an important part of B-cell physiology. It’s important in B-cell tumors in keeping those cells alive and making them resistant to treatment. Btk is one of a number of compounds under investigation that inhibits kinases downstream from the B-cell receptor. What was reported at ASCO 2011 relates to the Btk inhibitor PCI-32765. This is an oral agent that is also active in other B-cell tumors, including follicular lymphoma and mantle-cell lymphoma. Administration of PCI-32765 resulted in a significant reduction in lymph node size in the vast majority of patients with previously treated CLL. PCI-32765 is a well-tolerated agent. The main issues regarding toxicities with this drug relate to gastrointestinal toxicity, nausea, diarrhea and stomach upset. This is of particular importance considering the fact that so many of our current CLL treatments can cause cytopenias and infections or predispose to infections. I believe PCI-32765 is a promising new agent that has a high response rate in patients with CLL, including those with adverse risk factors such as 17p deletion. John P Leonard, MD